6533b825fe1ef96bd1283369

RESEARCH PRODUCT

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

Luisa AgnelloRoberto MuratoreMario BarbagalloSalvatore MilanoMarcello CiaccioNicola ScichiloneRosaria Vincenza GiglioBruna Lo SassoCaterina Maria GambinoGiulia BivonaConcetta Scazzone

subject

Lung DiseasesMalemedicine.medical_specialtySciencemedicine.medical_treatmentMR-proADMClinical BiochemistryComorbidityLabmed/1010Severity of Illness IndexGastroenterologyAdrenomedullinInterquartile rangeInternal medicineSeverity of illnessmedicineHumansAspartate AminotransferasesProtein PrecursorsSurvival analysisAgedRetrospective StudiesMechanical ventilationReceiver operating characteristicbiologyInterleukin-6SARS-CoV-2business.industryPatient SelectionBiochemistry (medical)C-reactive proteinCOVID-19Alanine TransaminaseRetrospective cohort studyMiddle AgedPrognosisSurvival Analysisrespiratory diseaseC-Reactive ProteininflammationHypertensionbiology.proteinbiomarkerBiomarker (medicine)FemaleTriagebusinessBiomarkersAcademicSubjects/MED00690

description

Abstract Objective The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3–2.95 vs median, 0.82 nmol/L; interquartile range, 0.57–1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001). Conclusion We found that MR-proADM could represent a prognostic biomarker of COVID-19.

yearjournalcountryeditionlanguage
2021-09-01Laboratory Medicine
https://doi.org/10.1093/labmed/lmab032